Zobrazeno 1 - 10
of 252
pro vyhledávání: '"TORU MUKOHARA"'
Autor:
Takehiro Nakao, Kenichi Harano, Masashi Wakabayashi, Yoichi Naito, Hiroshi Tanabe, Toru Mukohara
Publikováno v:
Gynecologic Oncology Reports, Vol 55, Iss , Pp 101482- (2024)
Objective: Platinum-free interval (PFI) is the period from the end of platinum-based chemotherapy to the date of recurrence. If the PFI is > 6 months, a platinum-based chemotherapy rechallenge is considered; however, its efficacy after poly adenosine
Externí odkaz:
https://doaj.org/article/531ab3d12ed3433ea0a6a2a65cf6a74f
Autor:
Kaede Baba, Megumi Kawamoto, Kanako Mamishin, Mao Uematsu, Hikari Kiyohara, Akira Hirota, Nobuyuki Takahashi, Misao Fukuda, Shota Kusuhara, Hiromichi Nakajima, Chikako Funasaka, Takehiro Nakao, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Toshikatsu Kawasaki, Toru Mukohara
Publikováno v:
Cancer Medicine, Vol 12, Iss 11, Pp 12095-12105 (2023)
Abstract Background Since it was first reported in December 2019, coronavirus disease 2019 (COVID‐19) spread rapidly across the globe resulting in a pandemic. As of August 2022, seven outbreak peaks have been confirmed in Tokyo, and the numbers of
Externí odkaz:
https://doaj.org/article/c0255b117bae403e9d5e854df13ba152
Autor:
Hiroji Iwata, Kenichi Yoshimura, Norikazu Masuda, Kenjiro Aogi, Yuko Tanabe, Koji Matsumoto, Masato Takahashi, Hitomi Sakai, Junji Tsurutani, Chiyo K Imamura, Tsutomu Iwasa, Toshimi Takano, Kiyoshi Yoshimura, Jun Masuda, Manabu Futamura, Mari Hosonaga, Toru Mukohara, Sakiko Miura, Toshiko Yamochi, Hidetaka Kawabata, Hiroyuki Yasojima, Nobumoto Tomioka
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background Hormone receptor (HR)-positive breast cancer is a disease for which no immune checkpoint inhibitors have shown promise as effective therapies. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors synergistically increased the effectiveness
Externí odkaz:
https://doaj.org/article/48eaa440eb16414586e7459b2d147b7c
Autor:
Chikako Funasaka, Akiko Hanai, Sadamoto Zenda, Keita Mori, Makoto Fukui, Nami Hirano, Rie Shinohara, Nozomu Fuse, Masashi Wakabayashi, Mai Itagaki, Yutaka Tomioka, Michihiko Nishina, Yasuaki Arai, Takahiro Kogawa, Yukinori Ozaki, Meiko Nishimura, Takayuki Kobayashi, Fumikata Hara, Toshimi Takano, Toru Mukohara
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundChemotherapy-induced peripheral neuropathy (CIPN) is one of the most common adverse events that can significantly impair the quality of life of patients. Although limb cooling may be beneficial for preventing CIPN, logistical challenges exi
Externí odkaz:
https://doaj.org/article/e1de7bd468ee4989bc20236eaa2dcef1
Autor:
Hiromichi Nakajima, Kenichi Harano, Tokiko Nakai, Shota Kusuhara, Takehiro Nakao, Chikako Funasaka, Chihiro Kondoh, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Shuichi Mitsunaga, Genichiro Ishii, Toru Mukohara
Publikováno v:
Breast, Vol 61, Iss , Pp 136-144 (2022)
Background: The previous second-line treatment for HER2-positive metastatic breast cancer were ado-trastuzumab emtansine (T-DM1); however, its activity is decreased in tumors with heterogenous, reduced, or loss of HER2 expression. Trastuzumab deruxte
Externí odkaz:
https://doaj.org/article/d024404aa0a9446f8558c9fcac6f4da6
Autor:
Michiyo Mizuno, Ikuko Chiba, Toru Mukohara, Miki Kondo, Kazushi Maruo, Tomohiro Ohigashi, Miki Naruo, Yoshihiro Asano, Tatsuya Onishi, Hiroshi Tanabe, Rieko Muta, Saori Mishima, Susumu Okano, Masami Yuda, Ako Hosono, Yuri Ueda, Hiroko Bando, Hiroya Itagaki, Carol Estwing Ferrans, Tetsuo Akimoto
Publikováno v:
Contemporary Clinical Trials Communications, Vol 30, Iss , Pp 101035- (2022)
Background: The aim of the trial is to evaluate the effectiveness of interventions provided by online support program apps, adopting health-related quality of life (HR-QOL) scores as indicators. Methods: The design is as an open, randomized, parallel
Externí odkaz:
https://doaj.org/article/f42c280edfd14d53b2fc8ca342384431
Autor:
Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, Tsutomu Iwasa, Masato Takahashi, Yuko Tanabe, Hidetaka Kawabata, Norikazu Masuda, Manabu Futamura, Hironobu Minami, Koji Matsumoto, Kenichi Yoshimura, Shigehisa Kitano, Toshimi Takano
Publikováno v:
Data in Brief, Vol 45, Iss , Pp 108558- (2022)
The purpose was to explore potential biomarkers of the efficacy and toxicity of triple therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer (MBC). Tumor tissues before treatment and blood samples at
Externí odkaz:
https://doaj.org/article/e0ddb6c5286c40f8a2dac63d5a45034c
Autor:
Chikako Funasaka, Yoichi Naito, Shota Kusuhara, Takehiro Nakao, Yoko Fukasawa, Kanako Mamishin, Ayumi Komuro, Mashiro Okunaka, Chihiro Kondoh, Kenichi Harano, Takahiro Kogawa, Nobuaki Matsubara, Ako Hosono, Toshikatsu Kawasaki, Toru Mukohara
Publikováno v:
Breast, Vol 58, Iss , Pp 50-56 (2021)
Background: Visceral crisis in metastatic breast cancer (MBC) is defined as severe organ dysfunction requiring rapidly efficacious therapy. Although weekly paclitaxel plus bevacizumab (wPTX + BV) achieves a high response rate in human epidermal growt
Externí odkaz:
https://doaj.org/article/1ee0cb78f98046edb5ecc170618af845
Autor:
Yumi Fujimoto, Tomoko Yamamori Morita, Akihiro Ohashi, Hiroshi Haeno, Yumi Hakozaki, Masanori Fujii, Yukie Kashima, Susumu S. Kobayashi, Toru Mukohara
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-16 (2020)
Abstract Amplification and/or overexpression of human epidermal growth factor receptor 2 (HER2) are observed in 15–20% of breast cancers (HER2+ breast cancers), and anti-HER2 therapies have significantly improved prognosis of patients with HER2+ br
Externí odkaz:
https://doaj.org/article/910a347264864bb197702e0d7f5cb41e
Autor:
Hirotoshi Iihara, Mototsugu Shimokawa, Masakazu Abe, Mitsue Saito, Toru Mukohara, Hironobu Hashimoto, Rie Ozeki, Hiroko Bando, Toshinobu Hayashi, Hitoshi Kawazoe, Masayo Komoda, Takako Yanai Takahashi
Publikováno v:
BMJ Open, Vol 12, Iss 3 (2022)
Introduction Triple antiemetic therapy with neurokinin-1 receptor antagonist, 5-hydroxytryptamine type 3 receptor antagonist, and dexamethasone has been widely recommended for high emetogenic chemotherapeutic (HEC) agents and regimens, including anth
Externí odkaz:
https://doaj.org/article/43e5a77aedcb4def83629d8a622a26e8